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Pre- and post-radiotherapy MRI results
as a predictive model for response in laryngeal
carcinoma
Abstract The purpose was to deter-
mine if pre-radiotherapy (RT) and/or
post-radiotherapy magnetic resonance
(MR) imaging can predict response in
patients with laryngeal carcinoma
treated with RT. Pre- and post-RT MR
examinations of 80 patients were
retrospectively reviewed and asso-
ciated with regard to local control.
Pre-RT MR imaging parameters such
as tumor involvement of specific
laryngeal anatomic subsites including
laryngeal cartilages and post-RT
changes, i.e., complete resolution of
the tumor or focal mass/asymmetric
obliteration of laryngeal tissue and
signal pattern on T2-weighted images,
were evaluated. Local control was
defined as absence of a recurrence at
the primary site for 2 years. Local
control rates based on pretreatment
MR findings were 73% for low pre-
RT risk-profile and 29% for high pre-
RT risk-profile patients (p=0.0001).
Based on posttreatment MR findings,
local control rates were 100% score 1,
64% score 2, and 4% score 3 (p<
0.0001). Using post-RT T2-weighted
images, significant association was
found between differences in signal
pattern and local control: 77% hy-
pointense, 54% isointense and 15%
hyperintense lesions (p<0.001). Dif-
ferences between means of delay of
post-MRI examination were signifi-
cantly associated with regard to local
control (p=0.003); recurrent tumors
followed 5 months after RTwere more
easily detectable on MRI than recur-
rent tumors within 4 months after RT.
Sensitivity, specificity, accuracy, neg-
ative and positive predictive values of
post-RT score 3 were 96%, 76%, 83%,
98% and 66%. Pre- and post-RT MRI
evaluation of the larynx can identify
patients at high risk for developing
local failure.
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Introduction
Imaging modalities like computed tomography (CT) and
magnetic resonance (MR) imaging are increasingly used in
follow-up of head and neck tumors. Promising results have
also been achieved for differentiation between residual or
recurrent head and neck tumors and postoperative or
postradiation changes with diffusion-weighted echo-planar
MR imaging [1]. However, the difference in pathology and
type of treatment and postradiation changes would
definitely affect the ADC value. The ability to provide an
accurate pretreatment prediction of response may offer a
possible opportunity to modify the initial treatment regimen
to improve clinical outcome.
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The preliminary studies suggest that with CT and MR
imaging it is possible to identify patients treated with
primary radiotherapy (RT) for squamous cell head and
neck cancer that are at increased risk for local recurrence
[2–11].
Residual or recurrent tumor after treatment can be
difficult to detect by physical examination due to the
radiation effects producing varying degrees of persistent
mucositis, edema and fibrosis and cartilage necrosis.
Approximately 50% of patients with severe edema or
necrosis following radiotherapy will have a recurrence
[12]. The need for biopsy itself can present a dilemma as
this may exacerbate postradiotherapy changes. Familiar-
ization with the expected imaging changes following
radiotherapy allows accurate evaluation of imaging studies
andmay prevent misinterpretation of posttreatment changes
as recurrent disease. Baseline imaging studies done
specifically for follow-up of the primary site are usually
obtained 3 to 4 months after completion of radiotherapy
[13, 14]. Until now, most studies focused on posttreatment
CT appearances of the irradiated larynx and indicated that
post-RT CT evaluations can identify patients at increased
risk for developing local recurrence and proved to be a
better prognosticator than the pretreatment CT risk profiles
[15–17]. The expected appearance of the irradiated larynx
at MR imaging has received limited attention in the
radiological literature [18]. Advantages of MR imaging
include superior soft tissue contrast and exact delineation
of tumor margins in arbitrary planes. Moreover, MR
imaging may identify fibrosis showing low signal intensity
(SI) in T1- and T2-weighted MR images, and consequently
may allow differentiation between tumor and fibrosis [19, 20].
On T2-weighted MR images signal intensity of tumors is
generally higher than signal intensity of fibrosis [19, 21, 22].
The purpose of this retrospective study is to determine if
pre-RT and/or post-RT MR imaging can predict the risk for
local failure in patients with laryngeal carcinoma treated
with irradiation alone or combined with chemotherapy.
Materials and methods
Patient selection
The hospital charts of 160 patients who underwent
radiation therapy with curative intent for squamous cell
carcinoma of the larynx between June 1995 and May 2003
were retrospectively reviewed. At least 24 months of
follow-up after completion of RT was required. Out of
these 160 patients, 80 (50%) were eligible for this study,
including 63 men (79%; mean age, 63 years; range, 39–
82 years) and 17 women (21%; mean age, 60 years; range,
45–71 years). The major reasons for exclusion were less
than 24 months’ follow-up after RT, patients with a
previous history of laryngeal cancer or other malignant
diseases in the head and neck region, and lack of suitable
MR imaging studies. Stage of disease in all patients was
appraised clinically according to the UICC recommenda-
tions [23]. The institutional review board waived patient
informed consent since all images were acquired for
clinical purposes and were considered as existing data
documents. The pretreatment tumor characteristics are
listed in Table 1.
All patients were treated with primary radiation therapy
with a mean total dose of 67 Gy (median, 70 Gy; range, 60–
70 Gy) using 2.0 to 2.5 Gy per fraction. Twelve patients
(15%) received neoadjuvant chemotherapy prior to radia-
tion therapy. Follow-up included indirect laryngoscopy at
2-month intervals in the first 2 years after finishing
radiation therapy and every 4–6 months thereafter,
supplemented in case of suspicion by direct laryngoscopy
under anesthesia with biopsies if indicated. No patient was
lost to follow-up. The follow-up period was designated as
the total time of follow-up ending either at local recurrence
or at last patient contact without local recurrence with a
minimum of 2 years (mean follow-up time, 23.7 months;
range, 4.5–107.7 months).
MR imaging
MR imaging was performed with a 1.0-T or 1.5-T MR
machine (Siemens-Impact or Vision, Erlangen, Germany).
A neck surface coil (Medical Advances, Milwaukee, WI) was
Table 1 Pretreatment tumor characteristics (n=80)
Variable Number of patients
Supraglottic site Glottic site % of total
T classification
T1 6 7
T2 12 32 55
T3 12 3 19
T4 8 7 19
N classification
N0 23 47 88
N1 8 1 11
N2 1 1
Vocal cord mobility (both sides)
Normal 23 19 53
Impaired 6 23 36
Fixed 3 6 11
Histopathology
Well differentiated 3 15 23
Moderately differentiated 22 26 60
Poorly differentiated 7 6 16
Undifferentiated 1 1
Primary treatment
Radiotherapy 22 46 85
Radiochemotherapy 10 2 15
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used for higher spatial resolution. Pre-RT MR images with
standard spin-echoT1-weighted (repetition timems/echo time
ms, 310–800/15), fast T2-weighted (2,200–4,550/90–98), and
contrast-enhanced T1-weighted images (310–800/15) were
available. Post-RT MR images were obtained in a similar
plane to that of the pre-RT non-contrast and contrast-enhanced
images.Other technical factors included a slice thickness of 3–
7 mm with a 1-mm intersection gap, and each acquisition
lasted approximately 2–5 min.
Two authors (JAC, RLJ) working in consensus, with
respectively 13 and 4 years of experience of head and neck
MR imaging, who were unaware of the patients’ clinical
findings retrospectively performed the imaging assessment
of all MRI studies. On pre-RT MRI examinations, each
tumor was assigned a low- or high-risk profile for local
failure after RT, based on previously determined specific
CT and MR imaging parameters [2, 11]. Patients with
supraglottic carcinoma were considered to be at high risk if
tumor invasion in the pre-epiglottic space in combination
with abnormal signal intensity of thyroid adjacent to the
anterior commissure and/or cricoid cartilage was present
[2]. A high-risk profile was attributed to a glottic carcinoma
if the tumor extended to the hypopharynx or if a tumor
mass demonstrated an intermediate T2 signal in cartilage
similar to tumor intensity [11]. In 14 patients the pretreat-
ment MRI study was not available. Determination of the
pretreatment risk profile in the patients who received RT
combined with neoadjuvant chemotherapy was based on a
MR imaging before initiation of chemotherapy.
The post-RT MRI examinations were evaluated for
changes using a three-point score [15, 16]: 1 = expected
post-RT changes, i.e., complete resolution of the tumor at
the primary site and symmetrically appearing laryngeal and
hypopharyngeal tissues (Fig. 1); 2 = focal mass with a
maximal diameter of less than 1 cm and/or asymmetric
obliteration of laryngeal tissue planes (Fig. 2); 3 = focal
mass with a maximal diameter of more than 1 cm, or less
than 50% estimated tumor volume reduction (Fig. 3).
According to preliminary experience with CT as imaging
method [14–16], this post-RT MRI scoring system can be
similarly interpreted as: 1 = likely to achieve permanent
local control, no evidence of disease; 2 = indeterminate,
suspicious for local failure or treatment complication; 3 =
indicated high likelihood of local failure. The MRI
examinations used for analysis were performed as part of
routine follow-up (n=51) or because of certain symptom-
atology, potentially indicating local recurrence (n=29).
The signal patterns of posttreatment changes were
observed on the T2-weighted images of post-RT MRI
examinations, but enhancement on post-contrast T1-
weighted images was evaluated if interpretation of T2
images was not optimal (Figs. 4, 5 and 6). The MR imaging
criteria for recurrent or residual tumor are an enlarging
enhancing infiltrating mass that is of intermediate to high
signal intensity on T2-weighted MR images [18, 24]. Areas
Fig. 1 Clinical stage T2 glottic carcinoma in a 63-year-old patient
with low pre-treatment MR risk profile. (A) Pre-treatment axial T1-
weighted MR image at the level of the true vocal cord shows a mass
(arrow) with intermediate signal intensity in the left cord. (B) Image
obtained 4 months post-RT (after radiation therapy) at the same
level. There is complete resolution of the tumor (arrowheads). The
laryngeal tissue appears symmetric and post-RT MR score is 1.
Local recurrence was not documented within 24 months after RT
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with very high signal intensity (equivalent to water) in T2-
weighted images were regarded as necrosis and not
included in this study. The hypointense areas were
considered as fibrotic changes [18].
All 80 patients in this study had undergone at least one
follow-up examination after radiation therapy. The 80
follow-up MR scans were obtained between 1 and
16 months after completion of radiotherapy (in 7 patients
more than 9 months). The mean time between completion
of radiotherapy and MRI was 5 months (median, 4 months).
Statistical analyses
The endpoint used in the statistical analyses was local
control at 2 years. Intervals were measured from the first
day of radiation therapy to the date of failure or the date of
last follow-up. The Kaplan-Meier method was used to
estimate curves and differences between curves we tested
by means of the log-rank test. Calculation of risk ratios and
simultaneous testing of pre-RT and post-RT MRI scores
were performed by Cox proportional hazards analysis. In
the analysis, post-RT MRI score was considered linearly
related with the log (hazard).
Tumor lesions on T2-weighted MR images after primary
treatment were classified into three groups, hypointense,
isointense/mixed and hyperintense, and were associated
using Cox regression model with regard to local control.
Differences in the means of delay of post-RT MRI exam-
ination were tested with a one-way analysis of variance.
The sensitivity, specificity, accuracy, and negative and
positive predictive values of follow-up MR imaging for
detection of local failure (score of 3) were calculated.
A p-value<0.05 was designated for determining signif-
icant differences. The SPSS version 11.0 (SPSS, Chicago,
IL) software package was used for analysis.
Results
The mean age at the time of radiotherapy was 63 years
(range, 39–82 years). There were no statistically significant
age-related differences between the male and female
patients (Mann-Whitney test, p=0.3), which matched the
sex ratio for laryngeal carcinoma.
A total number of 38 out 80 patients (48%) developed
local recurrence, which was confirmed by histopatholog-
ical examination. Six patients (6/12; 50%) were treated
with chemoradiation and 32 patients (32/68; 47%) with
irradiation alone. No significant difference was found
between these two groups. Thirty-four out of these 38
patients (89%) underwent salvage (partial) laryngectomy, 3
patients refused salvage treatment, and 1 patient died
suddenly after recurrent tumor was diagnosed.
Pre-RT MRI risk profile
In 66 out of 80 patients (83%) the pretreatment MR scans
were available for review. The pretreatment MR imaging
Fig. 2 Clinical stage T1b glottic carcinoma in a 62-year-old patient
with high pre-treatment MR risk profile. (A) Pre-treatment axial T1-
weighted MR image at the level of the true vocal cord shows a mass
(arrow) with intermediate signal intensity in the left cord. (B) MR
image at the same level, obtained at 7 months post-RT, shows that
the tumor has regressed, but there is asymmetric obliteration of the
fatty tissue at the left side without obvious focal mass. Post-RT MR
score is 2. There was no clinical evidence of disease
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high-risk parameters, as defined in the previous section, are
illustrated in Table 2. There were 26 patients with
supraglottic carcinoma (low-risk group, n=14; high-risk
group, n=12) and 40 patients with glottic carcinoma (low-
risk group, n=24; high-risk group, n=16). Figure 7
illustrates local control stratified by pre-RT MRI risk
profiles. At 2 years, the local control rate was approxi-
mately 73% in the low-risk group and 29% in the high-risk
group, which was statistically significant (95% CI: 1.9–8.5;
p=0.0001).
Fig. 3 Clinical stage T3 supraglottic carcinoma in a 64-year-old
patient with high pre-treatment MR risk profile. (A) Pre-treatment
axial T1-weighted MR image demonstrates a tumor mass (arrows)
with intermediate signal intensity on the left and right sides. (B) MR
image obtained 6 months after RT shows a focal mass (arrows) a
maximal diameter greater than 1 cm in the original tumor bed. This
image had MR score of 3. The patient developed a local failure at
9 months post-RT
Fig. 4 Clinical stage T2 glottic carcinoma in an 80-year-old patient.
Posttreatment axial T2-weighted MR image, obtained 11 months
after RT, at the level of the true vocal cord demonstrates a tumor
mass (arrowheads) with low signal intensity. The tumor was
considered as a hypointense tumor, which did not locally recur
within 24 months after RT
Fig. 5 Clinical stage T2 glottic carcinoma in a 78-year-old patient.
Posttreatment axial T2-weighted MR image, obtained 5 months after
RT, at the level of the true vocal cord demonstrates a tumor mass
(arrowheads) with low to intermediate to high signal intensity. The
tumor was considered as an isointense/mixed tumor, which locally
recurred within 9 months after RT
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Post-RT MRI score
The follow-up MR images of 80 patients were recorded by
using a three-point, post-radiation therapy changes scale,
and results were as follows: (1) score =1, i.e., 21 patients
with the complete remission after radiotherapy, 33 patients
with score 2, and 26 patients with MR imaging indicating
definite local failure (score=3).
Figure 8 illustrates the local control stratified for post-RT
MRI risk profiles. The local control rates at 2 years were
100% for score 1, 64% for score 2, and 4% for score 3,
which was statistically significant (95% CI: 4.2–15.5; p<
0.0001). The sensitivity, specificity, accuracy, and negative
and positive predictive values of use of follow-up MRI
examination for detection of local failure (post-RT MRI
score 3) were 96% (25/26), 76% (41/54), 83% (66/80),
98% (41/42), and 66% (25/38), respectively.
Combination of pre-RT MRI risk profile and post-RT
MRI score
In the group of patients classified as a low pretreatment risk
profile (n=38), 13 patients had posttreatment score 1 and
showed no local recurrence, whereas 8 patients with
posttreatment score 3 all failed locally. In the group with
posttreatment score 2 (n=17), 4 local recurrences occurred
(24%). Local control rates at 2 years were 100% for score
1, 60% for score 2, and 0% for score 3 (HR 7.3; 95% CI:
3.9–6330.9; p<0.001).
In patients with a high pretreatment risk profile (n=28),
3 patients had posttreatment score 1 and none of these cases
developed a local recurrence, whereas for 15 patients with
posttreatment score 3, 14 failed locally. In the group with
posttreatment score 2 (n=10), six local recurrences
occurred (60%). Local control rates at 2 years were
100% for score 1, 40% for score 2, and 7% for score 3 (HR
6.3; 95% CI: 1.2–6.8; p=0.01).
Post-RT MR imaging and local failure
Table 3 demonstrates the post-RT MRI examinations and
disease status (failure vs. not failure). In 25 out of the 38
patients with local failure, the findings of the first follow-up
MRI examination were classified as having a posttreatment
score of 3. One patient without local failure had posttreatment
score of 3 due to chondronecrosis and very pronounced edema
at clinical examination treated with hyperbaric oxygen
therapy. This patient remained free of local recurrence.
In 13 out of 38 patients with local failure, findings of first
post-RTMRI examination were classified as a posttreatment
score of 2. In four of these patients, an increase of the
posttreatment MRI score from 2 to 3 occurred over time. In
the other 4 of 13 patients, the follow-up MRI was only
Fig. 6 Clinical stage T4 supraglottic carcinoma in a 65-year-old
patient. Posttreatment axial T2-weighted MR image, obtained
3 months after RT, at the level of the false vocal cord shows a
tumor mass (arrowheads) with high signal intensity. The tumor was
considered as a hyperintense tumor, which locally recurred within
10 months after RT
Table 2 Pretreatment low-risk versus high-risk profile based MR imaging parameters
Site Number of patients % of total
Supraglottis
Low-risk 14 17.5
High-risk PES + abnormal SI of thyroid at ant.comissure 6 7.5
PES + abnormal SI of cricoid 6 7.5
No data avalaible 6 7.5
Glottis
Low-risk 24 30
High-risk Intermediate T2 signal in cartilage 15 19
Hypopharyngeal extension 1 1
No data avalaible 8 10
PES = pre-epiglottic space involvement; SI = signal intensity
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performed 3–7 months after RT, and diagnosis of tumor
recurrence was confirmed 1 to 5 months later.
None of the patients with a post-RTMRI score of 1 had a
tumor recurrence at the time of follow-up MR imaging.
In addition, in 10 out of 38 (26%) patients the local
failure was first suspected on routine MR imaging (post-RT
MRI score of 2 or 3). In six of these ten patients, these MRI
findings were confirmed within 2 months by histopatho-
logic examination. In the remaining four patients, no
immediate action was undertaken (not within 4 months
after radiologic diagnosis) because of the paucity of
clinical symptoms or lack of suspicious findings on direct
laryngoscopy.
From the entire patient population, 42 out of 80 patients
were examined after irradiation with MRI between 1 and
10 months (mean, 3.8 months; median, 3.6 months), and
these had no evidence of disease; in 25 out of 80 patients,
the post-RT MR imaging showed clearly the residual
disease suspected clinically with a mean delay of 7 months
(median, 5.2 months). In the remaining 13 out of 80
patients, post-RT MR imaging did not indicate recurrent
tumor, but these patients did develop a local failure with a
mean delay for post-RT MRI examination of 5 months
(median, 3.9 months). There was significant association
between means of delay of post-MRI examination (test of
variance, p=0.003).
Observed lesions on posttreatment T2-weighted MR
images
In T2-weighted MR images after radiation therapy, 35
tumors were hypointense (44%), 25 isointense/mixed
(31%), and 20 were hyperintense (25%) compared with
the signal intensity of the contralateral side of the larynx.
From the 38 patients that recurred locally, 9 patients had
hypointense tumor lesions (24%), 12 patients had iso-
intense (32%), and finally 17 patients had hyperintense
lesions (45%). Figure 9 illustrates local control stratified by
intensity on T2-weighted images after RT. At 2 years the
local control rates were 77% for hypointense, 54% for
isointense/mixed, and 15% for hyperintense lesions (95%
CI: 1.7–4.1; p<0.001).
Discussion
Monitoring the response to non-surgical treatment is one of
the challenges in head and neck oncology today. Accurate
Table 3 Detection of local recurrence and post-RT MRI examina-
tions (n=80)
Post-RT No local recurrence Local recurrence % of total
Score 1 21 0 26
Score 2 20 13 41
Score 3 1 25 33
Score 1 = likely achieved permanent local control; score 2 =
indeterminate; score 3 = suspicious for local failure
Fig. 7 Patients with a high pre-treatment MR risk profile showed poor
prognosis (2-year local control rate: 29%) compared to patients with a
low pre-treatment MR risk profile (2-year local control rate: 73%)
Fig. 8 Patients with a posttreatment MR risk profile of 3 showed
clearly poor prognosis (2-year local control rate: 4%) compared to
patients with posttreatment MR risk profiles of 1 and 2 (2-year local
control rate: 100% and 64%, respectively)
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evaluation of the response to RT by clinical examination
may be hampered by posttreatment fibrosis, edema,
inflammation, or scarring. According our study, combined
MR imaging before and after primary treatment may be
helpful in evaluating response in laryngeal carcinoma
treated by radiotherapy.
First, accurate pretreatment staging is essential for
planning of optimal therapy for patients with laryngeal
carcinoma, and data in this study provided valuable
information for identifying patients at high risk for local
recurrence. Around 42% of patients were retrospectively
identified as the high-risk pretreatment MRI group, which
means that the primary treatment chosen in these patients
may not have been optimal.
In this study, recurrence after radiotherapy may be
detected in an early stage on MR imaging. Especially the
identification of patients who are at high risk (post-RTMRI
score 3) for local failure was highly significant with regard
to local control. Only 1 out of 26 patients in the
posttreatment score 3 group remained free of disease at
the primary site and showed osteoradionecrosis, which
mimicked tumor recurrence. Our results are consistent with
CT studies that report 10% local control rate at 2 years for
patients in the score 3 group [15] and based on
posttreatment CT findings a high significance of predicting
the likelihood of local control in laryngeal carcinoma [15–
17]. Application of the post-RT MRI scoring system within
the two pretreatment risk groups resulted in an additional
separation within both groups into three risk groups for
local recurrence. In patients with both a low and high
pretreatment MRI risk profile, classification into the post-
RT MRI score 1 group was an infallible sign and proved to
be strongly predictive for local control. Three patients
classified as high risk on pre-RT MRI risk profile with a
favorable response to RT were identified on post-RT MRI
as a score 1 group and had no evidence of residual disease.
Moreover, eight patients with initially low pretreatment
MRI risk profile were identified as poor responders by
follow-up MRI examination, and these patients recurred
locally. Consequently, the post-RT MRI scoring system
was demonstrated to be a better prognosticator than
pretreatment MRI risk profile. Lell et al. [18] have reported
that the main criteria for recurrent/residual tumor in MR
imaging was infiltrative mass with intermediate signal
intensity on T1-weighted, high signal intensity in T2-
weighted and enhancement after Gd-DTPA in T1-weighted
MR images. They concluded that because of differences in
aspect, MR imaging proved to be better than CT in
characterizing recurrent lesions and in differentiation
between scar tissue and local tumor failure. According to
Engelbrecht et al. [20], the specificity of CT to detect
recurrence was 76% and of MRI was 86%. MRI is reported
to be more sensitive (92%) than CT (81%).
The potential role of MR imaging in distinguishing
tumor recurrence from radiation fibrosis on the basis of
signal intensity on long repetition time (TR)/echo time
(TE) (T2-weighted) pulse sequences for several head and
neck carcinomas treated with radiotherapy has been
described [21, 25, 26]. These studies conclude that tumors,
that appeared hyperintense on T2-weighted MR images
after radiation therapy were significantly correlated with
pathologic findings [25, 26]. In accordance with previous
studies, our results suggest that recurrent tumors may
appear as a hyperintense mass after contrast administration
in comparison with fibrotic changes after RT, which can be
seen as hypointense masses. However, the prolonged T2
value is not specific for tumor and may be seen in radiation
edema or infection. Three patients with a hyperintense
mass in our study proved to be false positive. Ebner et al.
[21] found that MR imaging was useful in distinguishing
recurrent tumors in the female pelvis from posttreatment
fibrosis in six patients. They emphasized that signal
intensities from radiation changes vary with time; fatty
replacement changes are seen, and abnormal soft tissue that
has decreased T2-weighted signal intensity is suggestive of
posttreatment scarring rather than recurrent tumor [18, 19,
27]. Arakawa et al. [28] also correlated MR imaging with
pathology in nine patients with tongue cancer who
underwent radiation or chemotherapy or both before
surgery, and suggested that dynamic and T2-weighted
MR imagings were considerably superior to contrast-
enhanced T1-weighted MR imaging in revealing tumor
mass. Hyperintensity on T2-weighted MR imaging in
Fig. 9 Patients with a hyperintense tumor mass on posttreatment
T2-weighted MR image showed very bad prognosis (2-year local
control rate: 15% compared to patients with a hypointense and
isointense/mixed tumor mass on posttreatment T2-weighted MR
image; 2-year local control rate: 77% and 54%, respectively)
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recurrent tumors may be caused by increased intracellular
water content of tumor cells and tumor edema.
CT findings of the laryngeal carcinoma within 3 to
6 months post-RT are reported to be often nonspecific [13,
14]. In our study the first MR study is performed 3–4 months
after RT to evaluate the primary site, assuming no strong
clinical suspicion of failure is present. MRI examination less
than 4 months after the end of RT may be very helpful as a
baseline, which may be useful to distinguish mass with
complete remission. These findings suggest that in the
posttreatment score 1 group, additional MRI follow-up is
actually not necessary, unless there is clinical suspicion of
recurrence. Moreover, the results of our study showed that
recurrence followed later than 5 months (median value) after
RT were detectable more easily on MR imaging than tumor
recurrence earlier than 4 months after RT. In accordance with
our results, Lell et al. [18] reported that in the first 3–
4 months, edema, tumor necrosis, and acute or chronic
inflammation lead to signal changes equivalent to tumor, but
with long intervals, these changes are minimized and
diagnosis is becoming more sufficient. Therefore, the use
of MR imaging for assessment of tumor recurrence within
4 months after the end of radiation therapy may not be
indicated. First post-RT MRI examination should be
performed at 4 months after the end of RT. Progression of
pathologic findings is strongly predictive of recurrence, such
that an early MR imaging might lead to earlier detection of
recurrence than those of clinical examination (26% of local
failure in this study). Patients with “suspicious” post-RTMR
study should be followed by imaging at regular intervals later
than 4 months, and therefore this might help any urge to
biopsy prematurely. This approach is supported by data from
FDG-positron emission tomography (PET) studies, showing
that baseline exams before 4 months post-RT may not
accurately reflect outcome, and that studies done at 4 months
and later result in a more accurate prediction of outcome [29,
30]. Keane et al. [31] supported routine reassessment with
biopsy 8–12 weeks after completion of radiation therapy to
detect recurrence as early as possible. Results of this study
suggest that use of post-RT MRI examination could reduce
substantially the number of patients needing biopsy.
The follow-up imaging of laryngeal carcinoma patients
treated with chemoradiotherapy generally shows no obvious
difference from those treated with radiation therapy alone. It
is important to note that, in this retrospective setting, no strict
follow-up protocol with repeat MR studies was followed.
Traditionally, the measurement of tumor volume has been
widely used for evaluating response after oncologic therapy,
and correlation with tumor control has been documented
[32–34]. We did not include MR volumetric tumor
evaluation after RT in our study due to factors contributing
to apparent tumor radioresistance; it was very difficult to
outline real tumor margins. Within the limitations of this
retrospective study, it can be concluded that the manual
drawing of the ROI area may result in some errors related to
the operator’s experiences and obscure the tumor margin.
Although our study is limited by no standard time for follow-
up of patients after primary treatment and subjective criteria
for the diagnosis of radiation change versus recurrent tumor
(observed lesions on T2 images), there was good intraob-
server and interobserver agreement.
Conclusion
In the evaluation of laryngeal carcinoma on post-RT MRI
examinations, symmetric post-RT changes without detect-
able mass are strongly indicative of ultimate control at the
primary site. When post-RT MRI shows a discrete mass or
asymmetric post-RT changes at the primary site, the pre-RT
MRI high-risk profile and hyperintense mass on T2-
weighted images after radiation therapy should be
suggestive for further workup in patients. Follow-up MR
study performed 4 months or later after RT appears to be a
reliable tool to refer a residual mass to scar tissue and is
recommended in addition to careful clinical follow-up.
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